Clinical course and outcomes of myocarditis after COVID-19 vaccination remain variable.
We retrospectively collected data on patients> 12 years old from 01/01/2021 to 12/30/2021 …

Background: Understanding the clinical course and short-term outcomes of suspected
myocarditis after the coronavirus disease 2019 (COVID-19) vaccination has important public …

Introduction Reports of SARS-CoV-2 coronavirus (COVID-19) vaccine-related myocarditis,
particularly after mRNA vaccines, have raised concerns amongst the general public. This …

Background The coronavirus disease of 2019 (COVID‐19) is a global pandemic with over
266 million cases and 5 million deaths worldwide. Anti‐COVID‐19 vaccinations have had …

Background: Following the roll-out of the Pfizer-BioNTech BNT162b2, Moderna mRNA-
1273, and Janssen Ad26. COV2. S coronavirus disease 2019 (COVID-19) injections in the …

Over 10 million doses of COVID‐19 vaccines based on RNA technology, viral vectors,
recombinant protein, and inactivated virus have been administered worldwide. Although …

Variable clinical criteria taken by medical professionals across the world for myocarditis
following coronavirus disease 2019 (COVID-19) vaccination along with wide variation in …

Myocarditis is recognized as a rare complication of coronavirus disease 2019 (COVID-19)
vaccinations, especially in young adult men and adolescent boys. 1, 2 Incidence is …

The risk of acute myocarditis associated with COVID-19 mRNA vaccination has garnered
intense (social) media attention. However, myocarditis after COVID-19 mRNA vaccination is …

Abstract Introduction: COVID-19, the infectious disease caused by severe acute respiratory
syndrome coronavirus-2 (SARS-CoV-2), often presents with a spectrum of symptoms at …